Allena Pharmaceuticals, Inc. EBIT Growth

EBIT Growth of ALNA for past 10 years: annual, quarterly and twelve month trailing (TTM) including EBIT Growth growth rates and interactive chart.


Highlights and Quick Summary

  • EBIT Growth for the quarter ending March 31, 2022 was -0.01 (a -5.15% decrease compared to previous quarter)
  • Year-over-year quarterly EBIT Growth decreased by -98.81%
  • Annual EBIT Growth for 2021 was -0.49 (a -253.85% decrease from previous year)
  • Annual EBIT Growth for 2020 was 0.32 (a -200.03% decrease from previous year)
  • Annual EBIT Growth for 2019 was -0.32 (a -54.47% decrease from previous year)
  • Twelve month EBIT Growth ending March 31, 2022 was -0.33 (a -32.12% decrease compared to previous quarter)
  • Twelve month trailing EBIT Growth increased by 200.27% year-over-year
Trailing EBIT Growth for the last four month:
31 Mar '22 31 Dec '21 30 Sep '21 30 Jun '21
-0.33 -0.49 -0.43 -0.11
Visit stockrow.com/ALNA for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical EBIT Growth of Allena Pharmaceuticals, Inc.

Most recent EBIT Growthof ALNA including historical data for past 10 years.

Interactive Chart of EBIT Growth of Allena Pharmaceuticals, Inc.

Allena Pharmaceuticals, Inc. EBIT Growth for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2022 -0.01
2021 -0.01 -0.57 -1.09 -0.52 -0.49
2020 0.12 0.41 0.42 0.35 0.32
2019 -0.15 -0.37 -0.39 -0.45 -0.32
2018 -0.49 -1.22 -0.82 -0.44 -0.7
2017 -0.08 0.55 0.45 0.3 -0.73
2016 0.07 -0.74
2015 0.43

Business Profile of Allena Pharmaceuticals, Inc.

Sector: Healthcare
Industry: Biotechnology
Allena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. Its lead product candidate is ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and gout in the setting of advanced chronic kidney disease. The company was incorporated in 2011 and is headquartered in Newton, Massachusetts.